Terlipressin is an effective and safe treatment for bleeding caused by rupture of oesophageal varices, which are life-threatening complications of liver cirrhosis. Oesophageal varices are abnormal dilatation of veins occurring in the lower oesophagus, which can develop in patients with cirrhosis. Bleeding caused by rupture of these varices is a life-threatening complication with mortality between 20-50%. Such bleeding can be treated with drug therapy and/or endoscopic; endoscopic therapy consists of a flexible tube equipped with a camera at the terminal end, allowing for visualizing and treating the oesophageal varices. In this study, investigators will evaluate the safety and efficacy of terlipressin - Glypressin 1 mg, powder and solvent for solution for injection. The non-interventional observational study "Follow-up of Glypressin (terlipressin) clinical efficacy in the treatment of bleeding oesophageal varices" aims to demonstrate that administration of Glypressin (terlipressin 1 mg) controls the bleeding in such patients.
Study Type
OBSERVATIONAL
Enrollment
20
Study drug (without placebo)
Emergency County Hospital - Surgery Clinic No.1
Târgu Mureş, Mureș County, Romania
To evaluate the clinical efficacy of Glypressin: measured by rapid control of heamorrhage; reduced mortality post-haemorrhage
Vital signs (blood pressure, heart rate, and body temperature) and routine safety lab analysis
Time frame: Up to 6 months
To evaluate the safety profile of Glypressin: measured by number of patients with adverse events
Time frame: Up to 6 months
To evaluate/monitor the ease of administration in ER
Easiness of use in ER (easy to reconstitute, easy to administer, flexible dosage)
Time frame: Up to 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.